Identifying targets for gene therapy of β-globin disorders using quantitative modeling approach

EMU I-REP

Show simple item record

dc.contributor.author Bashirov, Rza
dc.contributor.author Mehraei, Mani
dc.date.accessioned 2017-03-13T06:36:25Z
dc.date.available 2017-03-13T06:36:25Z
dc.date.issued 2017-08
dc.identifier.issn 0020-0255
dc.identifier.uri http://dx.doi.org/10.1016/j.ins.2017.02.053
dc.identifier.uri http://hdl.handle.net/11129/3186
dc.description The file in this item is the post-print version of the article (author’s copy; author’s final manuscript, accepted for publication after peer-review process). Due to copyright restrictions, the access to the publisher version (published version) of this article is only available via subscription. You may click URI and have access to the Publisher Version of this article through the publisher web site or online databases, if your Library or institution has subscription to the related journal or publication. en_US
dc.description.abstract Sickle cell disease and β-thalassemia are well-known genetic disorders which are caused by mutations in β-globin gene. Reactivation of fetal hemoglobin in adulthood through induction of γ-globin gene expression has proven be sufficient to ameliorate sickle cell disease and β-thalassemia. In the last few decades, substantial efforts have been made to identify potential target candidates for β-globin diseases. In the present work, we propose an innovative approach for identifying novel molecular targets of β-globin diseases. Our approach is based on quantitative modeling of fetal-to-adult hemoglobin switching network with hybrid functional Petri nets. We verify the coherence of deterministic quantitative model created in this research to be sure it is consistent with qPCR data available for known siRNA- and shRNA-based strategies. Comparison of simulation results for the proposed strategy with the ones obtained for already existing RNAi-mediated treatments shows that our strategy is optimal, as it leads to the highest level of γ-globin induction. Consequently, it has potential beneficial therapeutic effect on β-globin diseases. This study also provides an innovative strategy for the target-based treatment of many other diseases. en_US
dc.language.iso eng en_US
dc.publisher Elsevier en_US
dc.relation.isversionof dx.doi.org/10.1016/j.ins.2017.02.053 en_US
dc.rights info:eu-repo/semantics/openAccess en_US
dc.subject Hybrid functional Petri net en_US
dc.subject Quantitative modeling en_US
dc.subject Cell illustrator en_US
dc.subject β-thalassemia en_US
dc.subject Sickle cell disease en_US
dc.subject Fetal to adult hemoglobin switching network en_US
dc.title Identifying targets for gene therapy of β-globin disorders using quantitative modeling approach en_US
dc.type article en_US
dc.relation.journal Information Sciences en_US
dc.contributor.department Eastern Mediterranean University, Faculty of Arts and Sciences, Department of Mathematics en_US
dc.identifier.volume 397-398 en_US
dc.identifier.startpage 37 en_US
dc.identifier.endpage 47 en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record